AnaptysBio, Inc.

Equities

ANAB

US0327241065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/07/2024 BST			5-day change	1st Jan Change
32.71 ^USD	+8.67%		+28.43%	+52.71%

07-01	AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell Small Cap Comp Value Index	CI
07-01	AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell 3000 Value Index	CI

AnaptysBio, Inc. announces an Equity Buyback for $50 million worth of its shares.

January 13, 2023 at 02:03 pm

AnaptysBio, Inc. (NasdaqGS:ANAB) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its shares. The plan will be valid till December 31, 2023.

Latest news about AnaptysBio, Inc.

AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell Small Cap Comp Value Index	06-30	CI
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell 3000 Value Index	06-30	CI
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell 2500 Value Index	06-30	CI
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell 2000 Value Index	06-30	CI
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell Microcap Value Index	06-30	CI
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell 3000E Value Index	06-30	CI
AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis	05-09	CI
Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	04-16	MT
Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	04-11	MT
JPMorgan Adjusts Price Target on AnaptysBio to $28 From $30, Maintains Neutral Rating	04-01	MT
AnaptysBio, Inc.(NasdaqGS:ANAB) added to S&P Biotechnology Select Industry Index	03-17	CI
North American Morning Briefing : Stock Futures -2-	03-13	DJ
AnaptysBio Shares Jump on Upgrade by Wedbush	03-12	MT
Wedbush Upgrades AnaptysBio to Outperform From Neutral, Says Derivative, Clinical Catalysts to Drive Shares Higher; Raises PT to $34 From $20	03-12	MT
AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-11	CI
BTIG Initiates Coverage on AnaptysBio With Buy Rating, $55 Price Target	02-26	MT
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating	02-16	MT
Piper Sandler Initiates AnaptysBio at Overweight Rating With $80 Price Target	02-16	MT
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from S&P Biotechnology Select Industry Index	12-18	CI
GSK: EU approves Jemperli for endometrial cancer	12-11	CF
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	11-27	MT
Wedbush Lifts AnaptysBio's PT to $20 From $18 Due to Updated Cash Guidance, Keeps Neutral Rating	11-03	MT
AnaptysBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI

Chart AnaptysBio, Inc.

Duration

Period

More charts

Company Profile

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Sector

Biotechnology & Medical Research

Calendar

04/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for AnaptysBio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

32.71 USD

Average target price

43.78 USD

Spread / Average Target

+33.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANAPTYSBIO, INC.	+52.71%	894M
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
ARGENX SE	+24.98%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-17.24%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B

Bio Therapeutic Drugs